Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation

Ella Evron, Christopher B. Umbricht, Dorian Korz, Venu Raman, David M. Loeb, Birunthi Niranjan, Lakjaya Buluwela, Sigmund A. Weitzman, Jeffrey Marks, Saraswati Sukumar

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Cyclin D2 is a member of the D-type cyclins, implicated in cell cycle regulation, differentiation, and malignant transformation. It was noted previously that cyclin D2 is not expressed in the majority of breast cancer cell lines, whereas abundant expression was detected in finite life span human mammary epithelial cells. By reverse transcription-PCR and Western blot analysis, we extended this finding to primary breast carcinomas and show that the majority of these tumors lack expression of cyclin D2 mRNA (18 of 24) and protein (10 of 13). In contrast, both luminal and myoepithelial subpopulations of normal breast tissues expressed cyclin D2. Hypermethylation of the CpG island in the promoter was detected by methylation-specific PCR in nearly half of the breast cancers (49 of 106) and was associated with silencing of cyclin D2 gene expression. Promoter hypermethylation was also detected in ductal carcinoma in situ, suggesting that loss of cyclin D2 expression is an early event in tumorigenesis. Our results suggest that loss of cyclin D2 expression is associated with the evolution of breast cancer.

Original languageEnglish (US)
Pages (from-to)2782-2787
Number of pages6
JournalCancer Research
Volume61
Issue number6
StatePublished - Mar 15 2001
Externally publishedYes

Fingerprint

Cyclin D2
Breast Neoplasms
Breast
Cyclin D
Polymerase Chain Reaction
CpG Islands
Carcinoma, Intraductal, Noninfiltrating
Methylation
Reverse Transcription
Cell Cycle
Carcinogenesis
Western Blotting
Epithelial Cells
Gene Expression
Cell Line
Messenger RNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Evron, E., Umbricht, C. B., Korz, D., Raman, V., Loeb, D. M., Niranjan, B., ... Sukumar, S. (2001). Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Research, 61(6), 2782-2787.

Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. / Evron, Ella; Umbricht, Christopher B.; Korz, Dorian; Raman, Venu; Loeb, David M.; Niranjan, Birunthi; Buluwela, Lakjaya; Weitzman, Sigmund A.; Marks, Jeffrey; Sukumar, Saraswati.

In: Cancer Research, Vol. 61, No. 6, 15.03.2001, p. 2782-2787.

Research output: Contribution to journalArticle

Evron, E, Umbricht, CB, Korz, D, Raman, V, Loeb, DM, Niranjan, B, Buluwela, L, Weitzman, SA, Marks, J & Sukumar, S 2001, 'Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation', Cancer Research, vol. 61, no. 6, pp. 2782-2787.
Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Research. 2001 Mar 15;61(6):2782-2787.
Evron, Ella ; Umbricht, Christopher B. ; Korz, Dorian ; Raman, Venu ; Loeb, David M. ; Niranjan, Birunthi ; Buluwela, Lakjaya ; Weitzman, Sigmund A. ; Marks, Jeffrey ; Sukumar, Saraswati. / Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. In: Cancer Research. 2001 ; Vol. 61, No. 6. pp. 2782-2787.
@article{7bb9d3fe1a8845c8a67e956462f59fd9,
title = "Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation",
abstract = "Cyclin D2 is a member of the D-type cyclins, implicated in cell cycle regulation, differentiation, and malignant transformation. It was noted previously that cyclin D2 is not expressed in the majority of breast cancer cell lines, whereas abundant expression was detected in finite life span human mammary epithelial cells. By reverse transcription-PCR and Western blot analysis, we extended this finding to primary breast carcinomas and show that the majority of these tumors lack expression of cyclin D2 mRNA (18 of 24) and protein (10 of 13). In contrast, both luminal and myoepithelial subpopulations of normal breast tissues expressed cyclin D2. Hypermethylation of the CpG island in the promoter was detected by methylation-specific PCR in nearly half of the breast cancers (49 of 106) and was associated with silencing of cyclin D2 gene expression. Promoter hypermethylation was also detected in ductal carcinoma in situ, suggesting that loss of cyclin D2 expression is an early event in tumorigenesis. Our results suggest that loss of cyclin D2 expression is associated with the evolution of breast cancer.",
author = "Ella Evron and Umbricht, {Christopher B.} and Dorian Korz and Venu Raman and Loeb, {David M.} and Birunthi Niranjan and Lakjaya Buluwela and Weitzman, {Sigmund A.} and Jeffrey Marks and Saraswati Sukumar",
year = "2001",
month = "3",
day = "15",
language = "English (US)",
volume = "61",
pages = "2782--2787",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation

AU - Evron, Ella

AU - Umbricht, Christopher B.

AU - Korz, Dorian

AU - Raman, Venu

AU - Loeb, David M.

AU - Niranjan, Birunthi

AU - Buluwela, Lakjaya

AU - Weitzman, Sigmund A.

AU - Marks, Jeffrey

AU - Sukumar, Saraswati

PY - 2001/3/15

Y1 - 2001/3/15

N2 - Cyclin D2 is a member of the D-type cyclins, implicated in cell cycle regulation, differentiation, and malignant transformation. It was noted previously that cyclin D2 is not expressed in the majority of breast cancer cell lines, whereas abundant expression was detected in finite life span human mammary epithelial cells. By reverse transcription-PCR and Western blot analysis, we extended this finding to primary breast carcinomas and show that the majority of these tumors lack expression of cyclin D2 mRNA (18 of 24) and protein (10 of 13). In contrast, both luminal and myoepithelial subpopulations of normal breast tissues expressed cyclin D2. Hypermethylation of the CpG island in the promoter was detected by methylation-specific PCR in nearly half of the breast cancers (49 of 106) and was associated with silencing of cyclin D2 gene expression. Promoter hypermethylation was also detected in ductal carcinoma in situ, suggesting that loss of cyclin D2 expression is an early event in tumorigenesis. Our results suggest that loss of cyclin D2 expression is associated with the evolution of breast cancer.

AB - Cyclin D2 is a member of the D-type cyclins, implicated in cell cycle regulation, differentiation, and malignant transformation. It was noted previously that cyclin D2 is not expressed in the majority of breast cancer cell lines, whereas abundant expression was detected in finite life span human mammary epithelial cells. By reverse transcription-PCR and Western blot analysis, we extended this finding to primary breast carcinomas and show that the majority of these tumors lack expression of cyclin D2 mRNA (18 of 24) and protein (10 of 13). In contrast, both luminal and myoepithelial subpopulations of normal breast tissues expressed cyclin D2. Hypermethylation of the CpG island in the promoter was detected by methylation-specific PCR in nearly half of the breast cancers (49 of 106) and was associated with silencing of cyclin D2 gene expression. Promoter hypermethylation was also detected in ductal carcinoma in situ, suggesting that loss of cyclin D2 expression is an early event in tumorigenesis. Our results suggest that loss of cyclin D2 expression is associated with the evolution of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0035866809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035866809&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 2782

EP - 2787

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 6

ER -